%0 Generic
%A Paz-Ares, L.
%A Goto, Y.
%A Lim, W. D. T.
%A Halmos, B.
%A Cho, B. C.
%A Dols, M. Cobo
%A Gonzalez-Larriba, J. L.
%A Zhou, C.
%A Demedts, I.
%A Atmaca, A.
%A Baka, S.
%A Mookerjee, B. P.
%A Portella, S.
%A Zhu, Z.
%A Dharan, B.
%A Reck, M.
%T Canakinumab (CAN) plus docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
%D 2021
%@ 0923-7534
%U https://hdl.handle.net/10668/24516
%~